BELLUS Health Inc - Company Profile
Powered by 
All the data and insights you need on BELLUS Health Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date BELLUS Health Inc Strategy Report
- Understand BELLUS Health Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BELLUS Health Inc (BELLUS Health) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for treating patients with chronic cough and hypersensitization-related disorders. The company’s lead product, BLU-593 (formerly NEO5937) is a potent, orally bio-available, highly selective small-molecule antagonist of the P2X3 receptor which is being developed for treating refractory chronic cough, and chronic pruritus associated with atopic dermatitis. The company has license agreement and collaborations with NEOMED institute for the development and commercialization of BLU-593. The company operates in Canada and the US through its subsidiaries. BELLUS Health is headquartered in Laval, Quebec, Canada.
Headquarters
Canada
Address
275 Armand-Frappier Blvd, Laval, Quebec, H7V4A7
Website
bellushealth.com
Telephone
1 450 6804500
No of Employees
74
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$16,000
BELLUS Health Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| BLU-5937 (formerly NEO5937) : |
| Chronic Cough |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In April, GSK PLC announced its agreement to acquire the company. |
| 2022 | Official Trials/Tests | In July, the company announced the positive end of Phase 2 and its CLAM Phase 3 programe for BLU-5937. |
| 2020 | Contracts/Agreements | In March, the company entered into an agreement to purchase intellectual property assets from adMare BioInnovations. |
Competitor Comparison
| Key Parameters | BELLUS Health Inc | Pfizer Inc | Vanda Pharmaceuticals Inc | Cara Therapeutics Inc | VYNE Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | United States of America | United States of America |
| City | Laval | New York | Washington | Stamford | Bridgewater |
| State/Province | Quebec | New York | WashingtonD.C. | Connecticut | New Jersey |
| No. of Employees | 74 | 88,000 | 203 | 55 | 10 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Francesco Bellini | Chairman | Executive Board | 2010 | 75 |
| Roberto Bellini | Chief Executive Officer; Director; President | Executive Board | 2010 | 43 |
| Ramzi Benamar | Chief Financial Officer | Senior Management | 2020 | 50 |
| Andreas Orfanos | Chief Operating Officer | Senior Management | 2022 | 64 |
| Catherine M. Bonuccelli, MD | Chief Medical Officer | Senior Management | 2019 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward